Memo Therapeutics AG Broadcasts Constructive Part I Information with AntiBKV for Remedy of BKV An infection in Renal Transplant Sufferers

Scientific trial met main endpoint of security and tolerability

IND submission deliberate in Q1 2023 to provoke U.S. multicenter examine

ZURICH, January 24, 2023–(BUSINESS WIRE)–Memo Therapeutics AG (“MTx”), an innovator within the area of antibody discovery and growth, introduced at this time optimistic security and tolerability knowledge from a Part I medical trial with AntiBKV, an antibody focusing on BK polyomavirus (“BKV”) an infection in renal transplant sufferers, assembly its main endpoint.

On this part I, single-blind, partially randomized, placebo-controlled medical trial, 40 wholesome grownup volunteers had been administered single and a number of ascending intravenous doses of AntiBKV (ClinicalTrials.gov: NCT05358106). No related hostile occasions had been seen as much as the very best dose of 2000 mg and pharmacokinetics had been discovered to be regular and linear. MTx plans to submit an Investigational New Drug Utility (“IND”) in the course of the first quarter 2023 to provoke a multicenter examine within the U.S.

“This preliminary medical knowledge for AntiBKV may be very encouraging. We consider that AntiBKV, with its 100x stronger neutralization capability than benchmark antibodies, if confirmed in medical research, might current a game-changer for sufferers who’re presently significantly underserved,” stated Dr. Jürgen Beck, Chief Medical Officer of Memo Therapeutics AG.

“AntiBKV has the potential to be a best- and first-in-class antibody for the remedy of BKV an infection in kidney transplant recipients. With 50,000 kidney transplant procedures carried out within the US and Europe alone, AntiBKV addresses a big and quickly rising market, with an estimated measurement nicely past USD 1 billion,” stated Dr. Karsten Fischer, Chief Government Officer of Memo Therapeutics AG.

BKV an infection poses a big risk in kidney transplantation, with critical hostile results on graft operate and finally affected person survival. As a result of immunosuppressive drug routine, reactivation of BKV is triggered in 40 to 50% of kidney transplant recipients. As much as 10% of those circumstances progress to BKV related nephropathy, which poses a critical risk to the transplant. There’s presently no illness modifying remedy out there to deal with BKV an infection apart from the reducing of immunosuppression. Nevertheless, this considerably will increase the danger of a graft rejection response, resulting in impaired performance and longevity, or graft failure.

MTx was supported by Vakzine Project Management GmbH (“VPM”) primarily based in Hannover, Germany, chargeable for translational mission administration and medical trial oversight, and by Accelagen Pty Ltd (“Accelagen”) primarily based in Melbourne, Australia, for medical trial administration.

About Memo Therapeutics AG
Memo Therapeutics AG (“MTX”) is a clinical-stage biopharma firm creating best-in-class therapeutic antibodies to remodel the lives of sufferers with virus infections and most cancers. MTx’s lead program, AntiBKV, is a extremely efficient and secure neutralizing antibody to deal with BK virus an infection in kidney transplant recipients. This an infection can result in lack of kidney operate, in addition to organ failure and rejection. Memo’s pipeline consists of extra therapeutic antibodies specializing in infectious ailments, reminiscent of cytomegalovirus (“CMV”), in addition to undisclosed immuno-oncology targets.

The pipeline derives from MTx’s industry-leading throughput and purposeful screening capabilities, which might cowl your complete antibody repertoire. Utilizing its immortal cell libraries and distinctive nano droplet expertise, MTx identifies and isolates essentially the most potent antibodies primarily based on performance at an unprecedent fee, together with discovering ultra-rare antibodies that competing applied sciences fail to determine. MTx is a personal firm positioned in Schlieren / Zurich, Switzerland.

View supply model on businesswire.com: https://www.businesswire.com/news/home/20230123005445/en/

Contacts

Memo Therapeutics AG
Karsten Fischer
[email protected]

Halsin Companions
Mike Sinclair
+44 (0) 7968 022075
[email protected]